查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
中東·非洲的AI支援醫療影像市場
市場調查報告書
商品編碼
1803895

中東·非洲的AI支援醫療影像市場

MEA (Middle East & Africa) AI-assisted Medical Imaging Market
出版日期: | 出版商: Marketstrat, Inc. | 英文 24 Pages | 訂單完成後即時交付

價格

中東和非洲正從試點階段邁向規模化發展，其市場規模將從美國的2,500萬美元（2023年）成長至2032年的5億美元（複合年增長率為24%）。在撒哈拉以南非洲地區，低頻寬DR/超音波AI將透過營運支出模式和遠距放射學模式推廣。本報告提供了不同國家、不同醫療模式和不同買家在AI輔助醫學影像市場的佈局和勝利之道。

五大關鍵統計

  • 1. 規模與發展速度：2,500萬美元至5億美元（2023-2032年，複合年增長率為24%）。
  • 2. 海灣合作委員會（GCC）佔有率： 超過60%的區域支出（沙烏地阿拉伯、阿聯酋、卡達、科威特、阿曼、巴林）。
  • 3.到2032年，醫療模式組合變化：CT 佔 36%-23%，MRI 佔 32%-39%，X光/DR 佔 16%-22%。
  • 4. 臨床引擎：腫瘤科、心臟科和中風科將佔絕對成長的最大佔有率。
  • 5. 收入來源：在非洲，硬體佔有率將下降，軟體/服務佔有率將上升，雲端/按次付費將成長最快。

買方利益

  • 國家/地區策略（海灣合作委員會、北非、撒哈拉以南非洲）、行動、合作夥伴和定價原型。
  • CT/MR 捆綁套餐與 DR/美國營運成本方案的比較，並採用階梯式費率和平均售價區間。
  • 採購和託管清單（阿拉伯語使用者介面、資料駐留、GCC 安全/品質管理系統、非洲邊緣/離線）。
  • 證明預算一致性（從門到針、TAT、節省的劑量/時間）並獲得企業批准。
  • 框架驅動的 GTM（成長和成熟度、生態系統協作、解決方案採用和成長）。

方法論與品質保證：

雙視角模型：自上而下連結到全球總量，自下而上連結連結率驅動因素（出貨量、改造和平均銷售價格）。採用中東/非洲特定權重（SFDA/MOHAP/SAHPRA 訊號、捐贈者/PPP 模式），並總結了 QA 循環，涵蓋總計 <0.5%、監管差距檢查、證據新鮮度和 ASP 健康狀況。

特點

  • 涵蓋範圍：海灣合作委員會 (GCC)、北非和撒哈拉以南非洲地區；按治療方式、臨床區域、最終用途、收入來源、最終用途和國家細分。
  • 關鍵數據： 2,500 萬美元 → 5 億美元，複合年增長率 24%
  • 用例： OEM 捆綁包、純通路策略、Telerad 規模化、捐贈資助項目

目錄

章節1-摘要整理

章節2-調查手法

章節3-市場概要與分析-中東·非洲

  • 中東·非洲市場概述
  • 邏輯簇和重要性
  • 主要的成長催化劑
  • 結構性障礙與緩解措施
  • 供應商類別的實用的推薦事項
  • 定序藍圖
  • 執行的要點

章節4-市場預測-中東·非洲

  • 中東·非洲市場，各臨床領域(2023年～2032年)
  • 中東·非洲市場，各種模式(2023年～2032年)
  • 中東·非洲市場，不同收益來源(2023年～2032年)
  • 中東·非洲市場，各臨床用途(2023年～2032年)
  • 中東·非洲市場，各最終用途組織(2023年～2032年)
  • 中東·非洲市場，各AI技術(2023年～2032年)

章節5-MARKINTEL解決方案的招聘與成長矩陣-中東·非洲

  • 解釋和運用藍圖

章節6-MARKINTEL生態系統合作矩陣-中東·非洲

  • 夥伴關係劇本
  • 運用藍圖主要的實行指標

章節7-GTM概要(中東·非洲)

  • GTM 準備情況雷達 - 中東和非洲
  • 國家集群熱圖 - 中東和非洲
  • GTM 時間表 - 試點到規模化 (2024-2029) - 中東和非洲
  • 鄰近機會雷達 - 中東和非洲
  • GTM 成熟度亮點 - 中東和非洲
  • 監理速度 - 中東和非洲
  • 安裝率趨勢 - 中東和非洲
Product Code: MINTP-M01124

Report Headline:

MEA is shifting from pilots to selective scale-rising from ~US$25M (2023) to ~US$500M by 2032 (~24% CAGR). GCC anchors >60% of spend with enterprise AI suites, while Sub Saharan Africa scales low bandwidth DR/ultrasound AI via opex models and teleradiology. This Pulse translates evidence into where to play and how to win-per country, modality, and buyer.

Five Key Stats:

  • 1. Size & pace: ~US$25M -> ~US$500M (2023-2032, ~24% CAGR).
  • 2. GCC share: >60% of regional spend (KSA, UAE, Qatar, Kuwait, Oman, Bahrain).
  • 3. Modality mix shift: CT 36%->23%, MRI 32%->39%, X ray/DR 16%->22% by 2032.
  • 4. Clinical engines: Oncology, Cardiology, and Stroke account for most absolute growth.
  • 5. Revenue streams: Hardware share declines; Software/Service rise; Cloud/Pay per Use grows fastest in Africa.

Buyer Benefits:

  • Country specific playbooks (GCC, North Africa, Sub Saharan) with actions, partners, and pricing archetypes.
  • Attach rate ladders & ASP bands to package CT/MR bundles vs. DR/US opex offers.
  • Procurement & hosting checklists (Arabic UI, data residency, security/QMS for GCC; edge/offline in Africa).
  • Evidence to budget alignment (door to needle, TAT, dose/time saved) to unlock enterprise approvals.
  • Framework driven GTM (Growth & Maturity, Ecosystem Collaboration, Solution Adoption & Growth).

Methodology & QA:

Dual lens model: top down tie out to global totals + bottom up attach rate engine (shipments, retrofit, ASPs). MEA specific weighting (SFDA/MOHAP/SAHPRA signals; donor/PPP patterns). QA loop: sum to total less than or equal to 0.5%, regulatory diff checks, evidence freshness, ASP sanity.

Features at a glance:

  • Coverage: GCC, North Africa, Sub Saharan Africa; splits by modality, clinical area, application, revenue stream, end use, country
  • Key numbers: ~US$25M -> ~US$500M; ~24% CAGR
  • Use cases: OEM bundling, pure play channel strategy, telerad scale up, donor funded programs

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

  • The 25-second read
  • Size & Pace (where dollars concentrate)
  • Modality Mix (MEA, 2023 -> 2032)
  • Clinical pathways (MEA, 2023 -> 2032)
  • Revenue Stream Dynamics
  • Country/Cluster Snapshots
  • 12-month actions (MEA "Pulse Quick-wins")

SECTION 2 - RESEARCH METHODOLOGY

  • Scope & Segmentation
  • Dual-Lens Architecture
  • MEA-Specific Inputs & Weighting
  • Assumptions & calibration choices (MEA)
  • Quality assurance (standard Pulse QA)
  • Limitations & Mitigations

SECTION 3 - MARKET OVERVEW & ANALYSIS - MEA

  • MEA Market Snapshot
  • Logical Clusters & Why They Matter
  • Key Growth Catalysts
  • Structural Barriers & Mitigation
  • Actionable Recommendations by Vendor Type
  • Sequencing Roadmap
  • Executive Takeaways

SECTION 4 - MARKET ESTIMATES & FORECASTS - MEA

  • MEA Market by Clinical Area (2023-2032)
    • Growth Drivers & Restraints
  • MEA Market by Modality (2023-2032)
    • Modality Share Shifts
  • MEA Market by Revenue Stream (2023-2032)
    • Revenue Stream Shifts & Strategic Implications
  • MEA Market by Clinical Application (2023-2032)
    • Clinical Application Shifts & Takeaways
  • MEA Market by End-Use Organization (2023-2032)
    • End-User Adoption Patterns
  • MEA Market by AI Technology (2023-2032)
    • Technology Shifts and Takeaways

SECTION 5 - MARKINTEL SOLUTION ADOPTION & GROWTH MATRIX - MEA

  • Interpretation & Operating Roadmap
    • Execution Checklist

SECTION 6 - MARKINTEL ECOSTSYSTEM COLLABORATION MATRIX - MEA

  • Partnership Playbook
  • Operating Roadmap & Key Execution Metrics

SECTION 7 - GTM AT-A-GLANCE (MEA)

  • GTM Readiness Radar - MEA
  • Country Cluster Heatmap - MEA
  • GTM Timeline - Pilot to Scale (2024-2029) - MEA
  • Adjacency-Opportunity Radar - MEA
  • GTM Maturity Highlights - MEA
  • Regulatory Velocity - MEA
  • Attach Rate Trends - MEA

List of Figures

  • Figure 1: Markintel Solution Adoption & Growth Matrix - MEA
  • Figure 2: Markintel Ecosystem Collaboration Matrix - MEA
  • Figure 3: GTM Readiness Radar - MEA
  • Figure 4: Country Cluster Heatmap - MEA
  • Figure 5: GTM Timeline - Pilot to Scale (2024-2029) - MEA
  • Figure 6: Adjacency-Opportunity Radar - MEA
  • Figure 7: Regulatory Velocity - MEA
  • Figure 8: Attach Rate Trends - MEA

List of Tables

  • Table 1: Middle East and African (MEA) Market by Clinical Area (2023-2032, USD Million)
  • Table 2: Middle East and African (MEA) Market by Modality (2023-2032, USD Million)
  • Table 3: Middle East and African (MEA) Market by Revenue Stream (2023-2032, USD Million)
  • Table 4: Middle East and African (MEA) Market by Clinical Application (2023-2032, USD Million)
  • Table 5: Middle East and African (MEA) Market by End-Use Organization (2023-2032, USD Million)
  • Table 6: Middle East (MEA) Market AI Technology (2023-2032, USD Million)